Elekta AB (publ) (0O5H.IL) Stock
Elekta AB (publ)

Company profile
Elekta AB (publ) reported revenue of 16.72 billion SEK for fiscal year 2026, down 7.2% from fiscal year 2025. In Q1 2027 (the quarter ended July 31, 2026) revenue was 3.54 billion SEK, down 3.0% from a year before. In Q1 2027 it reported net income of 264.00 million SEK, against net income of 107.00 million SEK a year earlier. Our analysis of its filings shows revenue shrinking from 18.12 billion SEK in fiscal year 2024 to 16.72 billion SEK in fiscal year 2026, 3.9% a year on average. Elekta AB (publ) reports about 4,700 full-time employees.
What stands out
- It reported a net loss of 519.00 million SEK in fiscal year 2026, after a profit of 237.00 million SEK in fiscal year 2025.
Figures from company filings; latest fiscal year ended April 30, 2026.
About Elekta AB (publ)
Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity for real-time MR visualization; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for image guided radiation therapy; treatment and workflow management solutions; radiation and medical oncology; and other patient services. It also provides Elekta Studio, an image guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Venezia applicator that enables the oncologist to treat locally advanced cervical cancer; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; Geneva, an applicator for cervical cancer treatment; veterinary radiation therapy products; and Elekta Kaiku for personalized cancer care. In addition, the company offers stereotactic radiosurgery, such as Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for radiosurgeons; and Elekta Esprit. Further, it provides neurosurgery products comprising Leksell Vantage Stereotactic System for intracranial neurosurgery; and Leksell Stereotactic System for minimally invasive stereotactic neurosurgery. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.
Leadership
- Gustaf Salford — Pres & CEO, 45
- Laurent Leksell — Founder & Chairman, 70
- Tobias Hagglov — Chief Financial Officer, 44
- Anna Conneryd Lundgren — Exec. VP & Chief People Officer, 37
- Habib Nehme — Chief Commercial Officer, 58
How much revenue does Elekta AB (publ) make?
Elekta AB (publ) reported 16.72 billion SEK in revenue for fiscal year 2026, down 7.2% from 18.02 billion SEK in fiscal year 2025. In Q1 2027 revenue was 3.54 billion SEK.
What companies are similar to Elekta AB (publ)?
Listed companies of a similar size in the same industry (targeted healthcare equipment) include Getinge AB (publ) (0GZV.IL), Creo Medical Group PLC (CREO.L), Inspiration Healthcare Group plc (IHC.L), Cizzle Biotechnology Holdings Plc (CIZ.L).
Has Elekta AB (publ) made a profit in recent years?
Net income by fiscal year: FY2022, 1.15 billion SEK; FY2023, 943.00 million SEK; FY2024, 1.30 billion SEK; FY2025, 237.00 million SEK; FY2026, a loss of 519.00 million SEK. It reported a net loss in 1 of these 5 years.
Company Information
Data as of .
How to cite: DataPorium, “Elekta AB (publ) (0O5H.IL)”, data as of Jul 31, 2026, https://dataporium.tech/stocks/0O5H.IL